Precigen (NASDAQ:PGEN) CEO Sells $2,042,864.04 in Stock

Precigen, Inc. (NASDAQ:PGEN) CEO Helen Sabzevari sold 346,836 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the sale, the chief executive officer owned 3,768,872 shares of the company’s stock, valued at approximately $22,198,656.08. This represents a 8.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Sabzevari also recently made the following trade(s):

• On Thursday, May 28th, Helen Sabzevari sold 119,250 shares of Precigen stock. The stock was sold at an average price of $4.36, for a total transaction of $519,930.00.

Precigen Stock Performance

Shares of PGEN stock opened at $5.64 on Friday. The company has a current ratio of 4.82, a quick ratio of 4.12 and a debt-to-equity ratio of 4.62. The company has a market cap of $2.01 billion, a PE ratio of -4.78 and a beta of 1.00. The company’s fifty day simple moving average is $4.49 and its 200-day simple moving average is $4.25. Precigen, Inc. has a 52 week low of $1.47 and a 52 week high of $6.04.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. The firm had revenue of $23.25 million during the quarter, compared to analysts’ expectations of $20.81 million. As a group, equities research analysts anticipate that Precigen, Inc. will post -0.02 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PGEN. Citigroup reaffirmed an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Zacks Research upgraded Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. HC Wainwright boosted their price target on Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Citizens Jmp boosted their price target on Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Precigen has an average rating of “Hold” and an average price target of $12.50.

Institutional Investors Weigh In On Precigen

Hedge funds and other institutional investors have recently bought and sold shares of the business. State of Wyoming purchased a new position in shares of Precigen during the 1st quarter valued at approximately $27,000. NBC Securities Inc. bought a new stake in shares of Precigen in the fourth quarter worth $38,000. Mason Investment Advisory Services Inc. bought a new stake in shares of Precigen in the fourth quarter worth $42,000. Abel Hall LLC bought a new stake in shares of Precigen in the fourth quarter worth $44,000. Finally, Royal Bank of Canada raised its holdings in Precigen by 102.6% in the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 5,426 shares in the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.